Skip to content

Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space

Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02289573
Enrollment
15
Registered
2014-11-13
Start date
2014-11-30
Completion date
2015-06-30
Last updated
2014-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Chronic obstructive pulmonary disease(COPD) is a common disease among people. Acute exacerbation of chronic obstructive pulmonary disease(AECOPD) is the acute and aggravating phase of COPD which may lead to respiratory failure. Mechanical ventilation is a very important therapy for those patients,but traditional ventilation modes have some defects, so investigators need to find new modes to solve these problems. In this study, the investigators compare neurally adjusted ventilatory assist (NAVA) and PSV to observe the effects on AECOPD patients' air distribution and dead space to determine if NAVA is a more appropriate ventilation mode for AECOPD patients.

Interventions

DEVICENAVA and PSV

change ventilation modes(NAVA and PSV) with different support levels

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* AECOPD patients who need invasive mechanical ventilation * Patients who can tolerate assist mechanical ventilation * Patients who have signed ICF

Exclusion criteria

* Patients who are younger than 18 years old or older than 75 years old * Patients whose respiratory center is severely inhibited * Patients who can not stand NAVA gastric tube * Patients who have coagulation disorders * Patients whose vital signs are unstable * Patients who are in other clinical trails

Design outcomes

Primary

MeasureTime frame
the ratio of physiologic dead space over tidal volume (VD/VT)1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026